Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
ICICI Lombard General Insurance disclosed a corporate governance lapse after draft, unaudited December-quarter financial information was inadvertently shared on a...
New Delhi: States sought greater special assistance for capital investments, and enhanced support to compensate for revenue loss due to...
New Delhi: India is likely to be represented by minister of electronics and IT Ashwini Vaishnaw at a key meet...
As Venezuelan detainee Diógenes Angulo left a prison in San Francisco de Yare after a year and five months behind...
Thousands of people marched in Minneapolis Saturday to protest the fatal shooting of a woman by a federal immigration officer there and...
The U.S. has launched another round of retaliatory strikes against the Islamic State in Syria following last month’s ambush that killed two...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
